Gainers
- Theriva Biologics TOVX shares moved upwards by 33.5% to $1.66 during Thursday's regular session. The market value of their outstanding shares is at $2.2 million.
- Verrica Pharmaceuticals VRCA shares rose 31.53% to $1.46. The company's market cap stands at $62.2 million.
- Bone Biologics BBLG stock rose 30.98% to $1.99. The company's market cap stands at $3.5 million.
- OS Therapies OSTX stock increased by 20.96% to $3.52. The company's market cap stands at $73.5 million.
- TransCode Therapeutics RNAZ stock rose 20.84% to $0.6. The market value of their outstanding shares is at $10.3 million.
- Cue Biopharma CUE stock rose 17.26% to $0.86. The company's market cap stands at $51.7 million.
Losers
- Windtree Therapeutics WINT shares decreased by 21.5% to $1.13 during Thursday's regular session. The market value of their outstanding shares is at $1.8 million.
- AngioDynamics ANGO stock declined by 17.13% to $6.34. The company's market cap stands at $257.6 million. The company's, Q1 earnings came out today.
- Soligenix SNGX stock fell 16.64% to $4.06. The company's market cap stands at $9.2 million.
- TNF Pharmaceuticals TNFA stock decreased by 15.7% to $1.45. The market value of their outstanding shares is at $3.4 million.
- BeyondSpring BYSI shares declined by 14.01% to $2.21. The market value of their outstanding shares is at $89.0 million.
- GlucoTrack GCTK shares decreased by 12.85% to $1.96. The market value of their outstanding shares is at $10.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BBLGBone Biologics Corp
$0.9500-3.87%
BYSIBeyondSpring Inc
$1.69-3.43%
CUECue Biopharma Inc
$0.9899-4.82%
GCTKGlucoTrack Inc
$0.26440.15%
OSTXOS Therapies Inc
$3.975.03%
RNAZTransCode Therapeutics Inc
$3.51-1.86%
SNGXSoligenix Inc
$2.77-2.45%
TNFATNF Pharmaceuticals Inc
$1.23-4.65%
TOVXTheriva Biologics Inc
$1.4813.8%
VRCAVerrica Pharmaceuticals Inc
$0.70830.68%
WINTWindtree Therapeutics Inc
$0.3100-4.62%
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in